Saldanha G, et al. - In view of the observation that histomorphologic prognostic biomarkers using only a hematoxylin and eosin stain are simple and cheap, researchers proposed the Breslow density (BD), an entirely novel biomarker of this type, which measures invasive melanoma cell density at the site where Breslow thickness (BT) is measured. They noted that BD can be measured accurately and precisely. It was observed to have independent prognostic value and explained melanoma-specific survival (MSS) better than BT alone. In this work, they also demonstrated the utility of BD with American Joint Committee on Cancer version 8 staging.